Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome [Systems Biology]

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are diseases of abnormal hematopoietic differentiation with aberrant epigenetic alterations. Azacitidine (AZA) is a DNA methyltransferase inhibitor widely used to treat MDS and AML, yet the impact of AZA on the cell-surface proteome has not been defined. To identify potential therapeutic targets...

http://bit.ly/2sg4nf5